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cardiomyopathy (ARVD/C) complicate family screening.
OBJECTIVES The objective of the present study was to determine the optimal approach to longitudinal follow-up
regarding: 1) screening interval; and 2) testing strategy in at-risk relatives of ARVD/C patients.
METHODS We included 117 relatives (45% male, age 33.3  16.3 years) from 64 families who were at risk of developing
ARVD/C by virtue of their familial predisposition (72% mutation carriers [92% plakophilin-2]; 28% ﬁrst-degree relatives
of a mutation-negative proband). Subjects were evaluated by electrocardiography (ECG), Holter monitoring, signal-
averaged ECG, and cardiac magnetic resonance (CMR). Disease progression was deﬁned as the development of a new
criterion by the 2010 Task Force Criteria (not the “Hamid criteria”) at last follow-up that was absent at enrollment.
RESULTS At ﬁrst evaluation, 43 subjects (37%) fulﬁlled an ARVD/C diagnosis according to the 2010 Task Force Criteria.
Among the remaining 74 subjects (63%), 11 of 37 (30%) with complete re-evaluation experienced disease progression
during 4.1  2.3 years of follow-up. Electrical progression (n ¼ 10 [27%], including by ECG [14%], Holter monitoring
[11%], or signal-averaged ECG [14%]) was more frequently observed than structural progression (n ¼ 1 [3%] on CMR). All
5 patients (14%) with clinical ARVD/C diagnosis at last follow-up had an abnormal ECG or Holter monitor recording, and
the only patient with an abnormal CMR already had an abnormal ECG at enrollment.
CONCLUSIONS Over a mean follow-up of 4 years, our study showed that: 1) almost one-third of at-risk relatives have
electrical progression; 2) structural progression is rare; and 3) electrical abnormalities precede detectable structural
changes. This information could be valuable in determining family screening protocols. (J Am Coll Cardiol 2014;64:
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ABBR EV I A T I ON S
AND ACRONYMS
ARVD/C = arrhythmogenic
right ventricular dysplasia/
cardiomyopathy
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
ECG = 12-lead
electrocardiography
ICD = implantable
cardioverter-deﬁbrillator
IQR = interquartile range
RV = right ventricle/ventricular
SAECG = signal-averaged
electrocardiography
TFC = Task Force Criteria
VT = ventricular tachycardia
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294ARVD/C is made in an index patient with pos-
itive gene identiﬁcation, guidelines exist on
the optimal testing strategy to diagnose
ARVD/C in ﬁrst-degree relatives (5,6).SEE PAGE 302However, in our experience, only a subgroup
of at-risk family members meet diagnostic
Task Force Criteria (TFC) for ARVD/C at the
time of their initial evaluation; the majority
have minor electrocardiographic (ECG) cri-
teria or reveal no additional criteria other
than the positive family history (7). Although
guidelines exist on how to evaluate at-risk
family members at an initial visit, both the
optimal longitudinal screening strategy and
the timing of subsequent evaluations to
monitor development of ARVD/C criteria areunknown. Periodic reassessment with ECG recording,
Holter monitoring, and echocardiography/cardiac
magnetic resonance (CMR) imaging is performed by
many referral centers, including ours, but objective
evidence to support this approach is lacking. The
burden on clinical resources is signiﬁcant, as is the
psychosocial impact on patients and their families (8).
As such, there is an enormous need for objective data
on the impact of serial screening on both the devel-
opment of ARVD/C criteria and clinical outcome in
these at-risk people. The purpose of our study was to
examine the utility of serial noninvasive follow-up
evaluation in individuals at risk of developingARVD/C.
METHODS
STUDY POPULATION. The study population was
recruited from the Johns Hopkins ARVD/C registry
(9). For the purpose of this study, we identiﬁed
all families in which the proband fulﬁlled 2010
diagnostic TFC for ARVD/C (6) and had undergone
comprehensive genetic testing for an ARVD/C-
associated mutation in 5 desmosomal genes. 1)
Among families with a mutation-positive proband,
we included all relatives who were genotyped and
found to carry the same mutation as the proband.
Nongenotyped and mutation-negative relatives were
excluded. 2) Among families with a mutation-
negative proband, we included all ﬁrst-degree rela-
tives of the proband. According to clinical practice
and genetics guidelines (5), genetic testing is not
recommended in relatives of a mutation-negative
proband, although a genetic cause of ARVD/C
cannot be ruled out. Therefore, we only included
ﬁrst-degree relatives of a mutation-negative proband.This yielded a total of 239 relatives from 107
families who were regarded as being at risk of
developing ARVD/C. Among these subjects, 117 sub-
jects underwent at least 1 full evaluation that
included 12-lead ECG and CMR with the images
available for analysis. Therefore, the study popula-
tion comprised 117 relatives from 64 families who
were regarded as being at risk of developing ARVD/C
and who underwent full evaluation with the studies
available for analysis. A patient ﬂowchart is shown
in Figure 1. The majority of subjects were at risk
by virtue of the presence of an ARVD/C-associated
pathogenic mutation (n ¼ 84; 92% plakophilin-2;
Online Table 1); the remainder were ﬁrst-degree
relatives of a mutation-negative ARVD/C proband
(n ¼ 33). All patients provided written informed con-
sent. The Johns Hopkins School of Medicine Institu-
tional Review Board approved the study.
CLINICAL CHARACTERIZATION. The 2010 TFC were
used for clinical characterization of family members
(6) and not the criteria proposed by Hamid et al. (7).
Patients were evaluated as described previously (10).
All 117 subjects underwent routine 12-lead ECG
(recorded at rest; 10 mm/mV at paper speed 25 mm/s),
which was evaluated for repolarization (precordial
T-wave inversion in V1 to V2 or beyond) or depolari-
zation (epsilon waves or terminal activation dura-
tion $55 ms) criteria for ARVD/C (6). No subject
was taking antiarrhythmic or other medications
known to affect the QRS complex at the time of ECG
acquisition. In addition, 24-h Holter monitoring was
evaluated for premature ventricular complex count,
which according to the 2010 TFC was regarded as
abnormal if >500 premature ventricular complexes
were recorded (6). Exercise stress testing and loop re-
cordings were evaluated for evidence of (non)sus-
tained ventricular tachycardia (VT). Signal-averaged
ECG (SAECG) recordings, obtained by time-domain
analysis with a band-pass ﬁlter of 40 Hz, were evalu-
ated for evidence of late potentials. SAECG was regar-
ded as abnormal if 1 of 3 parameters showed evidence
of late potentials, as stated in the 2010 TFC (6).
CMR examinations for all 117 subjects were per-
formed according to standard protocols for ARVD/C,
which have been described previously in detail
(11,12). All CMRs were acquired on a 1.5T scanner
with a phased-array cardiac coil during repeated end-
expiratory breath holds. ECG-gated cine images, fast
spin-echo images, and contrast-enhanced images
after administration of a gadolinium chelate were
acquired in both axial and short-axis planes covering
the entire right ventricle (RV) and left ventricle.
Global ventricular volumes and function were
Family members with full evaluation
including 12-lead ECG and CMR at baseline
n=117
Fulfilling TFC at baseline
n=43
Not fulfilling TFC at baseline
n=74
Repeat evaluation
n=37
No repeat evaluation
n=37
FIGURE 1 Patient Flowchart
Determination of the study population. CMR ¼ cardiac magnetic resonance; ECG ¼
electrocardiogram; TFC ¼ Task Force Criteria.
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295calculated from the short-axis cine images with the
software program QMASS (Medis, Leiden, the
Netherlands). Three experienced CMR physicians
blinded to all other patient information performed
the CMR image analysis. CMR studies were analyzed
for fulﬁllment of diagnostic criteria for ARVD/C
according to the revised 2010 TFC (6).
FOLLOW-UP AND OUTCOME MEASURES . This
study’s primary outcome was the diagnosis of
ARVD/C according to the revised 2010 TFC (6), and
not according to the criteria as described by Hamid
et al. (7). Because all subjects were either an
ARVD/C-associated pathogenic mutation carrier or a
ﬁrst-degree relative of a mutation-negative ARVD/C
proband, they all received a major criterion for family
history. Therefore, an additional 2 minor criteria or 1
major criterion sufﬁced for meeting diagnostic
criteria for ARVD/C. In addition, we describe fulﬁll-
ment of the criteria for familial ARVD/C as previously
described by Hamid et al. (7) in the Online Appendix
(Online Tables 2 and 3). As a secondary outcome, we
ascertained the occurrence of a life-threatening ven-
tricular arrhythmia, which was a composite measure
of the occurrence of spontaneous sustained VT,
aborted sudden cardiac death, sudden cardiac death,
or appropriate implantable cardioverter-deﬁbrillator
(ICD) intervention for a ventricular arrhythmia, as
described previously (10).
STATISTICAL ANALYSIS. All continuous data are
presented as mean SD or median (interquartile range
[IQR]) and categorical variables as numbers (percent-
ages). Continuous variables were compared between 2
groups with the independent Student t test or Mann-
Whitney U test; comparisons between 3 groups were
performed with analysis of variance or Kruskal-Wallis
test. Categorical data were compared with the chi-
square test or Fisher exact test where appropriate. To
evaluate differences between baseline and last follow-
up for continuous variables, paired Student t tests
were used. For categorical variables, the proportion of
disease progression (i.e., 2010 TFC fulﬁllment) was
estimated with the Clopper-Pearson 95% conﬁdence
interval (CI). The freedom from disease progression
(i.e., 2010 TFC fulﬁllment) was evaluated by Kaplan-
Meier analysis. A p value of <0.05 was considered
signiﬁcant. Statistical calculations were performed
with SPSS version 21.0 (IBM, Chicago, Illinois).
RESULTS
STUDY POPULATION. The study population com-
prised 117 relatives from 64 families who were at risk
of developing ARVD/C. Characteristics of the studyparticipants are shown in Table 1. Mean age at ﬁrst
evaluation was 33.3  16.3 years, and 53 patients
(45%) were men. The majority (n ¼ 72 [61%]) of
subjects were asymptomatic at presentation; the
remainder (n ¼ 45 [39%]) had a history of syncope,
presyncope, or palpitations.
DEFINITE ARVD/C DIAGNOSIS AT ENROLLMENT.
Results for baseline clinical evaluation are shown in
Table 1. At ﬁrst evaluation, 43 subjects (37%) were
diagnosed with ARVD/C according to the 2010 TFC.
Mean age of these patients was 36.0  14.3 years, and
15 (35%) were male (Table 1). Patients with deﬁnite
ARVD/C were more often symptomatic than subjects
without ARVD/C diagnosis (26 [61%] vs. 19 [26%];
p < 0.001). All 43 patients with deﬁnite ARVD/C had
electrical abnormalities on ECG, Holter monitor, or
SAECG (Table 1). Structural changes on CMR were
observed in 21 subjects (49%).
NO ARVD/C DIAGNOSIS AT ENROLLMENT. Basel ine
eva luat ion . Overall, 74 subjects (63%) did not have
an ARVD/C diagnosis according to the 2010 TFC at ﬁrst
evaluation. These patients were 31.7  17.3 years of
age at time of ﬁrst evaluation, and 38 (51%) were male.
At enrollment, 31 (42%) of these subjects had minor
electrical abnormalities on ECG, Holter monitoring, or
SAECG; none met TFC on CMR (Table 1).
Disease progress ion . Patients without ARVD/C
diagnosis were followed for a mean period of 4.1  2.3
years. Disease progression was deﬁned as the devel-
opment of a new ECG, Holter monitoring, SAECG, or
CMR TFC according to the 2010 TFC at last follow-up
that was absent at enrollment. Among 37 subjects
with a complete re-evaluation, 28 (76%) were muta-
tion carriers.
TABLE 1 Baseline Characteristics of Family Members
Overall
(n ¼ 117)
No ARVD/C ARVD/C
p Value†
Completely Normal Evaluation
(n ¼ 40)
Borderline/Suspected ARVD/C*
(n ¼ 34)
Deﬁnite ARVD/C Diagnosis*
(n ¼ 43)
Age at enrollment (yrs) 33.3  16.3 28.5  16.9 35.5  17.2 36.0  14.3 0.038
Male 53 (45) 17 (43) 21 (62) 15 (35) NS
Mutation carrier 84 (72) 27 (68) 24 (71) 33 (77) NS
Symptomatic 45 (39) 9 (23) 10 (29) 26 (61) 0.001
Palpitations 36 (31) 9 (23) 9 (27) 18 (42) NS
Syncope 11 (9) 4 (10) 0 (0) 7 (16) NS
Pre-syncope 15 (13) 4 (10) 3 (9) 8 (19) NS
ECG, Holter monitor, or SAECG fulﬁlling TFC 74 (63) 0 (0) 31 (91) 43 (100) NS
ECG fulﬁlling TFC 46 (39) 0 (0) 11 (32) 35 (81) <0.001
T-wave inversion V1 to V3 24 (21) 0 (0) 0 (0) 24 (56) <0.001
T-wave inversion V1 and V2 11 (9) 0 (0) 4 (12) 7 (16) 0.034
T-wave inversion V4 to V6 4 (3) 0 (0) 1 (3) 3 (7) NS
T-wave inversion V1 to V4 in presence of CRBBB 1 (1) 0 (0) 0 (0) 1 (2) NS
Epsilon wave 1 (1) 0 (0) 0 (0) 1 (2) NS
Prolonged TAD 8 (7) 0 (0) 6 (18) 2 (5) 0.009
Holter monitoring fulﬁlling TFC‡ 19/91 (16) 0/26 (0) 2/30 (7) 17/35 (49) <0.001
PVC count 10 (1–267) 2 (0–10) 2 (0–46) 462 (39–2,558) <0.001
SAECG fulﬁlling TFC§ 40/86 (74) 0/29 (0) 23/32 (72) 17/25 (68) <0.001
CMR fulﬁlling TFC 21 (18) 0 (0) 0 (0) 21 (49) <0.001
RV wall motion abnormalities 31 (27) 1 (3) 4 (12) 26 (61) <0.001
RV EDV/BSA (ml/m2) 81.2  25.8 70.7  12.6 81.7  21.1 95.0  26.1 <0.001
RVEF (%) 51.1  8.3 54.6  7.1 52.4  6.5 47.2  9.0 0.004
LVEF (%) 57.7  6.5 59.0  6.8 58.2  5.7 56.0  6.6 NS
Values are mean  SD, n (%), median (interquartile range), or n/N (%). *Borderline/suspected ARVD/C deﬁned as 3 TFC points; deﬁnite ARVD/C deﬁned as$4 TFC points. The 2010 revised TFC were used for
diagnostic categorization, and not the Hamid criteria. †p value constitutes comparison of all 3 groups. ‡Holter monitoring fulﬁlled TFC when >500 PVCs/24 h. §SAECG fulﬁlled TFC when at least 1 of 3
parameters was abnormal.
ARVD/C ¼ arrhythmogenic right ventricular dysplasia/cardiomyopathy; BSA ¼ body surface area; CMR ¼ cardiac magnetic resonance; CRBBB ¼ complete right bundle branch block; ECG ¼ electrocar-
diogram; EDV ¼ end-diastolic volume; IQR ¼ interquartile range; LVEF ¼ left ventricular ejection fraction; NS ¼ not signiﬁcant; PVC ¼ premature ventricular complex; RV ¼ right ventricular; RVEF ¼ right
ventricular ejection fraction; SAECG ¼ signal-averaged electrocardiogram; TAD ¼ terminal activation duration; TFC ¼ Task Force Criteria.
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296Eleven subjects (30%) showed evidence of disease
progression (Fig. 2). Five (45%) of these subjects
were men, with a mean age of 29.3  16.0 years
(median, 22.0 years; IQR: 15.0 to 42.5 years) at time
of ﬁrst evaluation. The vast majority of these pa-
tients (10 of 11 [91%]) showed evidence of electrical
progression on ECG, Holter monitor, or SAECG.
Electrical progression was frequently observed on
ECG (n ¼ 5 [14%, 95% CI: 5% to 29%]). Holter
monitoring progression was observed in 3 of 27
subjects (11%; 95% CI: 2% to 29%). SAECG showed
evidence of late potentials in 3 of 22 subjects (14%;
95% CI: 3% to 35%). In addition to the 10 patients
with progression on ECG, Holter monitoring, or
SAECG, 1 patient (3%) had a run of nonsustained VT
of left bundle branch block superior axis morphology
on exercise testing, thereby fulﬁlling a major
arrhythmia TFC that was absent at enrollment. None
of the tests that were abnormal at baseline reverted
to normal during follow-up (Online Fig. 1). A graphic
representation of disease progression is shown in
Figure 3.Online Figure 2 and Online Table 4 show the prev-
alence of CMR ﬁndings in 37 subjects with serial
structural evaluation. One patient had structural pro-
gression and fulﬁlled a minor 2010 TFC for CMR at last
follow-up. This patient, who also had nonsustained VT
during exercise testing, already had an abnormal ECG
with T-wave inversions in V1 and V3 (not V2) both at
enrollment and at last follow-up. Her baseline CMR
showed RV dyskinesia with borderline RV end-
diastolic volume of 88.3 ml/m2 and an RV ejection
fraction of 50%,which increased to an RV end-diastolic
volume of 93.5 ml/m2 and RV ejection fraction of 45%
at last follow-up, thereby fulﬁlling a minor CMR TFC
according to the 2010 TFC. In the overall group, RV and
left ventricular volumes and function did not change
signiﬁcantly during follow-up (Online Fig. 2).
Outcome. Five subjects (14%) with an initially normal
clinical evaluation were diagnosed with ARVD/C ac-
cording to the 2010 TFC during follow-up. Their clin-
ical characteristics are described in Table 2. There was
no statistically signiﬁcant difference in length of
follow-up between those with and without a deﬁnite
Electrical Progression (ECG, Holter, SAECG)
Structural Progression (CMR)
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FIGURE 3 Time to Disease Progression Among 37 Subjects With Complete
Re-Evaluation
*Per study design, time to progression (i.e., fulﬁllment of TFC) and time to
last follow-up were the same or within a 1-year range for electrical and
structural progression in all subjects. Therefore, numbers at risk apply to both
electrical and structural progression. CMR ¼ cardiac magnetic resonance;
ECG ¼ electrocardiogram; SAECG ¼ signal-averaged electrocardiogram;
TFC ¼ Task Force Criteria.
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TFC 3
n=13
TFC 2
n=24
TFC 2
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TFC ≥ 4
n=5
Baseline
Last Follow-up
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1610
FIGURE 2 Disease Progression in 37 Subjects With Complete Re-Evaluation
Disease progression (deﬁned as the development of a new 2010 TFC at last follow-up that
was absent at enrollment) is shown as red dotted lines; numbers in red depict the number
of patients. ARVD/C ¼ arrhythmogenic right ventricular dysplasia/cardiomyopathy;
TFC ¼ Task Force Criteria.
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297ARVD/C diagnosis (median 5.9 [IQR: 2.7 to 7.2] years
vs. 3.6 [IQR: 2.4 to 5.1] years; p ¼ NS). The majority
of subjects (n ¼ 4 [80%]) with deﬁnite ARVD/C were
female, with a median age of 39.0 years (IQR: 19.5 to
51.0 years) at the time of diagnosis.
Patients fulﬁlling the 2010 TFC for ARVD/C at last
follow-up were more often symptomatic at enroll-
ment (3 of 5 [60%] vs. 4 of 32 [13%] asymptomatic;
p ¼ 0.012) and more often had an abnormal baseline
ECG (2 of 5 [40%] vs. 1 of 32 [3%] with a normal ECG;
p ¼ 0.005) than patients who did not fulﬁll ARVD/C
TFC at last follow-up. All other clinical characteristics
and tests at enrollment were similar between those
with and without a deﬁnite ARVD/C diagnosis at last
follow-up. Among all clinical tests at last follow-up,
SAECG was the only modality that did not distin-
guish between patients with and without a deﬁnite
ARVD/C diagnosis (1 of 2 [50%] vs. 9 of 25 [36%];
p ¼ NS).
ADVERSE EVENTS. Among the overall cohort, 29 of
117 subjects (25%) had an ICD, all of whom had a
deﬁnite ARVD/C diagnosis at the time of ICD im-
plantation. During 4.1  2.3 years of follow-up, none
of the 74 subjects without deﬁnite ARVD/C diagnosis
at ﬁrst evaluation experienced a sustained ventricular
arrhythmia. In comparison, 8 of 43 patients with
ARVD/C diagnosis at ﬁrst evaluation (19%) experi-
enced an arrhythmic event during 3.2  2.4 years of
follow-up. Two events were spontaneous sustained
VTs, and 6 were appropriate ICD discharges. All
patients who experienced an arrhythmic event were
successfully diagnosed with ARVD/C before the
arrhythmia. No subjects died or required heart
transplantation during follow-up.
DISCUSSION
Our study aimed to describe the utility of serial
noninvasive follow-up evaluation in at-risk family
members of ARVD/C probands (predominantly
plakophilin-2 mutation carriers). This study has
several interesting results. First, we showed that rel-
atives of ARVD/C probandswho did not fulﬁll 2010 TFC
for ARVD/C at ﬁrst evaluation had a low short-term risk
of sustained arrhythmia during a mean follow-up of 4
years. Second, during the 4-year follow-up period, we
only observed minimal disease progression, which
should be taken into account when determining the
optimal screening interval for these patients. Third,
electrical progression on ECG, Holter monitoring, or
SAECG was seen to a much greater extent than struc-
tural progression on CMR, and all patients with a def-
inite ARVD/C diagnosis at last follow-up had an
abnormal ECG or Holter monitor. These results add tothe growing body of evidence that electrical abnor-
malities precede detectable structural changes in
ARVD/C, which should be reﬂected by the screening
strategy used in these subjects (Central Illustration).
FAVORABLE PROGNOSIS. The high risk of ventricu-
lar arrhythmias in ARVD/C is well established. How-
ever, the arrhythmic propensity of the index patient
must not necessarily be applied to at-risk relatives,
who by virtue of the incomplete penetrance and
TABLE 2 Characteristics of 5 Patients With a Deﬁnite ARVD/C Diagnosis at Last Follow-up
Patient #1 Patient #2 Patient #3 Patient #4 Patient #5
Sex F F M F F
Age at time of diagnosis (yrs) 21 43 59 39 18
Pathogenic mutation  þ (PKP2) þ (PKP2) þ (PKP2) þ (PKP2)
Length of follow-up (yrs) 5.9 6.2 8.2 2.4 2.8
Symptoms Palpitations Palpitations, pre-syncope Palpitations, pre-syncope Palpitations, syncope Palpitations
Disease progression
Electrical progression* Yes Yes Yes Yes Yes
Repolarization progression BL: None
FU: TWI V1 to V3
. . . BL: None
FU: TWI V1 to V2
Arrhythmia progression . BL: 1 PVC/24 h
FU: 502 PVCs/24 h
BL: 29 PVCs/24 h
FU: 1,105 PVCs/24 h
BL: None
FU: LBS NSVT
BL: 2 PVCs/24 h
FU: 4,559 PVCs/24 h
Depolarization progression . . . . BL: None
FU: > TAD
Structural progression† No No No Yes No
Clinical phenotype
Repolarization TFC TWI V1 to V3 (major) TWI V1 and V2 (minor) None None TWI V1 and V2 (minor)
Depolarization TFC Late potentials (minor) None > TAD þ late potentials
(minor)
None > TAD (minor)
Arrhythmia TFC None 502 PVCs/24 h (minor) 1,105 PVCs/24 h (minor) Nonsustained VT, LBBB
superior axis (major)
4,559 PVCs/24 h (minor)
Structural TFC None None None Minor None
Family history TFC Major Major Major Major Major
TFC points at enrollment 3 3 3 2 2
TFC points at last follow-up 5 4 4 5 5
Disease progression was deﬁned as the presence of a new 2010 TFC at last follow-up that was absent at baseline. *Progression on electrocardiography, Holter monitoring, or signal-averaged
electrocardiography. †Progression on cardiac magnetic resonance imaging.
ARVD/C ¼ arrhythmogenic right ventricular dysplasia/cardiomyopathy; BL ¼ baseline; FU ¼ follow-up; LBBB ¼ left bundle branch block; LBS NSVT ¼ nonsustained ventricular tachycardia of left bundle
branch superior axis morphology; PKP2 ¼ plakophilin-2; PVC ¼ premature ventricular complex; > TAD ¼ prolonged terminal activation duration; TFC ¼ Task Force Criteria; TWI ¼ T-wave inversion;
VT ¼ ventricular tachycardia.
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lower level of risk (10). In fact, our study shows that
family members of ARVD/C patients who do not fulﬁll
diagnostic 2010 TFC at ﬁrst evaluation have a low risk
of arrhythmia during a mean follow-up of 4 years. It is
important to note in this regard that more than one-
third of at-risk relatives fulﬁlled diagnostic 2010
TFC for ARVD/C at ﬁrst evaluation, and that 8 of these
43 subjects experienced a ventricular arrhythmia
during follow-up. This emphasizes the importance
of complete screening in relatives after diagnosis in
a proband, and underscores the fact that the low risk
of arrhythmias in short-term follow-up only applies
to those who do not fulﬁll 2010 TFC at initial
evaluation.
DETERMINING THE OPTIMAL SCREENING INTERVAL.
An important result of our study is that the overall
rate of progression in relatives of ARVD/C probands
is slow and unlikely to be appreciated on short-
term screening. Disease progression was observed
in 30% of subjects with an initially normal clinical
investigation during 4 years of follow-up. However,
only minimal changes were observed for all single
testing modalities between baseline and last follow-
up. These results are in alignment with prior reportsthat showed limited change on electroanatomic
scar mapping and CMR during a follow-up period
of approximately 4 years (13,14). This lack of
short-term progression is important to consider when
re-evaluating family members of ARVD/C index
patients at a 2- to 3-year interval. The pre-test prob-
ability of ﬁnding new abnormalities is low, and
the observed changes are likely to be minor, with
questionable clinical signiﬁcance. Although our mean
follow-up duration was relatively short, and the
results by no means provide deﬁnite reassurance for
patients at risk of developing ARVD/C, these data
provide important information for clinical care, in
which follow-up protocols are still largely based
on consensus opinions and clinical judgments. One
recent study from our group described that endurance
exercise and frequent physical activity contribute to
disease development and arrhythmic occurrence in
ARVD/C-associated desmosomal mutation carriers
(15), which suggests that at-risk individuals should
not participate in high-level athletics. It is certainly
possible, and perhaps likely, that the absence of dis-
ease progression that we observed in the present
study may not apply to subjects who continue to
participate in athletic training.
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299DETERMINING THE OPTIMAL SCREENING STRATEGY.
Over the past decade, CMR has gained enormous
popularity as the modality of choice for structural
evaluation in ARVD/C. However, in our cohort of
subjects with high a priori risk of ARVD/C, there
was only 1 patient with an initially normal struc-
tural evaluation who had a minor CMR criterion
at last follow-up. In addition, other qualitative CMR
parameters, such as RV delayed enhancement
and fat, did not increase the yield of CMR
screening.
On the basis of a cross-sectional study in ARVD/C
mutation carriers, we have previously proposed that
electrical abnormalities precede detectable struc-
tural changes in people at risk of developing
ARVD/C (16). This is also supported by a study by
Protonotarios et al. (17), which reported on 205 at-
risk subjects who were similarly followed over a
median of 4 years. In their study, 16 mutationCENTRAL ILLUSTRATION Disease Progression in ARVD/C
Family members of a proband with arrhythmogenic right ventricular dy
symptoms of disease (concealed stage). Electrical changes on electroca
abnormalities may be observed later. Disease progression is typically slo
ventricular; TWI ¼ T-wave inversion.carriers were newly diagnosed with ARVD/C during
follow-up, of whom 100% had ECG abnormalities,
whereas only 31% had structural alterations. The
present study extends prior reports by showing
that electrical abnormalities are not only more
prevalent in a cross-sectional setting in ARVD/C,
but also precede structural abnormalities in a
longitudinal fashion. Only 1 patient in this study
had structural progression on CMR, but whether
this really represents disease progression is argu-
able. This patient already had an abnormal CMR
with RV free wall dyskinesia at baseline and showed
a minimal volume increase (RV end-diastolic volume
increased from 88.3 ml/m2 to 93.5 ml/m2), ful-
ﬁlling a minor TFC. Moreover, she had an abnor-
mal ECG with T-wave inversion in leads V1 and V3
(but not V2) and a run of nonsustained VT on exercise
testing, which fulﬁlled a major arrhythmia TFC for
ARVD/C.splasia/cardiomyopathy (ARVD/C) have a long latent stage without signs or
rdiogram or Holter monitoring are usually the ﬁrst sign of disease, and structural
w. ECG ¼ electrocardiogram; PVC ¼ premature ventricular complex; RV ¼ right
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
ARVD/C is a slowly progressive disease in which
electrical abnormalities precede detectable structural
changes.
COMPETENCY IN PATIENT CARE 1: After
comprehensive evaluation of relatives of patients
with ARVD/C, physicians may reassure those not
fulﬁlling the 2010 Task Force criteria that pro-
gression occurs slowly, if at all, and that the risk of
arrhythmia is generally low.
COMPETENCY IN PATIENT CARE 2: Cardiac
magnetic resonance imaging of relatives of patients
with ARVD/C may be restricted to subjects who are
symptomatic and those with depolarization or repo-
larization abnormalities on ECG or Holter monitoring.
TRANSLATIONAL OUTLOOK: Genetic character-
ization and longer-term follow-up of families of pa-
tients with ARVD/C are needed to deﬁne additional
factors associated with early and late development of
structural and electrical abnormalities.
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300Interestingly, all patients who fulﬁlled diagnostic
TFC for ARVD/C at last follow-up had electrical ab-
normalities on ECG or Holter monitor in addition to
their familial predisposition. This suggests that elec-
trical abnormalities precede detectable structural
changes in subjects at risk for ARVD/C. Importantly,
this study and prior reports have shown that no
single test should be relied upon for diagnosis and
risk stratiﬁcation purposes in ARVD/C, because even
a 12-lead ECG can be normal in deﬁnite ARVD/C
cases (18). Therefore, a full baseline evaluation re-
mains necessary in determining an at-risk in-
dividual’s phenotype. In our cohort, SAECG was the
only test that did not distinguish between subjects
with and without a deﬁnite ARVD/C diagnosis at last
follow-up. Although this calls into question the sig-
niﬁcance of an abnormal SAECG in the evaluation
of subjects at risk for ARVD/C, SAECG was shown to
have incremental value for ARVD/C evaluation among
newly diagnosed ARVD/C probands in a prior study
(19). Adding to the results of prior studies (10,17,18),
this supports a screening strategy that includes serial
ECG and Holter monitoring in all subjects at risk of
developing ARVD/C and using CMR in selected cases
when symptoms and/or ECG or Holter monitoring
abnormalities are present. Prior studies have shown
that arrhythmic risk in ARVD/C is very low in children
before the age of puberty (20). Further studies are
needed to validate our ﬁndings and identify the age
window at which screening is particularly likely to
detect disease expression.
STUDY LIMITATIONS. Studies on ARVD/C, in partic-
ular involving CMR, are typically small in size. Only
37 subjects without ARVD/C diagnosis at enrollment
underwent complete re-evaluation using at least
ECG and CMR. The other 37 subjects did not undergo
repeat CMR, but also re-evaluation by ECG was not
performed in the majority of these subjects. Because
baseline characteristics and endpoints were similar
between subjects with and without repeat evalua-
tion, a signiﬁcant selection bias seems unlikely.
The presence of multiple pathogenic mutations in
ARVD/C probands has been described previously
(21). Although only one pathogenic mutation was
identiﬁed in all mutation-positive families of this
study, the presence of modiﬁer genes could be
responsible for disease progression in some family
members. Although the majority of subjects carried a
pathogenic ARVD/C-causing mutation, a subset of our
cohort was made up of family members of a mutation-
negative proband. This provided us with the oppor-
tunity to study a reasonably large cohort of family
members at risk of developing disease. ICDs wereimplanted in 25% of our cohort, only among those
with a deﬁnite ARVD/C diagnosis. This may have
increased our ability to identify ventricular arrhyth-
mias among those with an ICD.
CONCLUSIONS
To the best of our knowledge, this study is the ﬁrst to
describe the yield of serial cardiac evaluation using a
combination of ECG, Holter monitoring, SAECG, and
CMR in at-risk relatives of ARVD/C probands. Our
results reassure the practicing physician that patients
who do not fulﬁll the 2010 revised TFC at ﬁrst eval-
uation have a low risk of arrhythmia during a mean
follow-up of 4 years. Disease progression is minimal
and likely not appreciated on biennial or triennial
screening. Because electrical abnormalities precede
detectable structural changes, the use of serial CMR
screening may be restricted to symptomatic family
members with electrical abnormalities on ECG and
Holter monitoring.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Harikrishna Tandri, Division of Cardiology, Depart-
ment of Medicine, The Johns Hopkins Hospital,
600 North Wolfe Street, Carnegie 538, Baltimore,
Maryland 21287. E-mail: htandri1@jhmi.edu.
J A C C V O L . 6 4 , N O . 3 , 2 0 1 4 te Riele et al.
J U L Y 2 2 , 2 0 1 4 : 2 9 3 – 3 0 1 Serial Evaluation in ARVD/C
301RE F E RENCE S1. Marcus FI, Fontaine GH, Guiraudon G, et al.
Right ventricular dysplasia: a report of 24 adult
cases. Circulation 1982;65:384–98.
2. Corrado D, Thiene G, Nava A, Rossi L,
Pennelli N. Sudden death in young competitive
athletes: clinicopathologic correlations in 22
cases. Am J Med 1990;89:588–96.
3. Nava A, Bauce B, Basso C, et al. Clinical proﬁle
and long-term follow-up of 37 families with
arrhythmogenic right ventricular cardiomyopathy.
J Am Coll Cardiol 2000;36:2226–33.
4. Dalal D, James C, Devanagondi R, et al.
Penetrance of mutations in plakophilin-2 among
families with arrhythmogenic right ventricular
dysplasia/cardiomyopathy. J Am Coll Cardiol
2006;48:1416–24.
5. Ackerman MJ, Priori SG, Willems S, et al.
HRS/EHRA expert consensus statement on the
state of genetic testing for the channelopathies
and cardiomyopathies. Heart Rhythm 2011;8:
1308–39.
6. Marcus FI, McKenna WJ, Sherrill D, et al. Diag-
nosis of arrhythmogenic right ventricular cardio-
myopathy/dysplasia: proposed modiﬁcation of
the task force criteria. Circulation 2010;121:
1533–41.
7. Hamid MS, Norman M, Quraishi A, et al. Pro-
spective evaluation of relatives for familial
arrhythmogenic right ventricular cardiomyopathy/
dysplasia reveals a need to broaden diagnostic
criteria. J Am Coll Cardiol 2002;40:1445–50.
8. James CA, Tichnell C, Murray B, Daly A,
Sears SF, Calkins H. General and disease-speciﬁc
psychosocial adjustment in patients with
arrhythmogenic right ventricular dysplasia/
cardiomyopathy with implantable cardioverter
deﬁbrillators: a large cohort study. Circ Car-
diovasc Genet 2012;5:18–24.9. Johns Hopkins Medicine, Heart & Vascular
Institute. Arrhythmogenic Right Ventricular
Dysplasia/Cardiomyopathy registry. Available at:
http://www.hopkinsmedicine.org/heart_vascular_
institute/clinical_services/centers_excellence/arvd/
index.html. Accessed June 14, 2014.
10. Bhonsale A, James CA, Tichnell C, et al. Risk
stratiﬁcation in arrhythmogenic right ventricular
dysplasia/cardiomyopathy-associated desmo-
somal mutation carriers. Circ Arrhythm Electro-
physiol 2013;6:569–78.
11. Tandri H, Calkins H, Nasir K, et al. Magnetic
resonance imaging ﬁndings in patients meeting
Task Force criteria for arrhythmogenic right ven-
tricular dysplasia. J Cardiovasc Electrophysiol
2003;14:476–82.
12. Dalal D, Tandri H, Judge DP, et al. Morphologic
variants of familial arrhythmogenic right ven-
tricular dysplasia/cardiomyopathy: a genetics-
magnetic resonance imaging correlation study.
J Am Coll Cardiol 2009;53:1289–99.
13. Riley MP, Zado E, Bala R, et al. Lack of uniform
progression of endocardial scar in patients with
arrhythmogenic right ventricular dysplasia/car-
diomyopathy and ventricular tachycardia. Circ
Arrhythm Electrophysiol 2010;3:332–8.
14. Conen D, Osswald S, Cron TA, et al. Value of
repeated cardiac magnetic resonance imaging in
patients with suspected arrhythmogenic right
ventricular cardiomyopathy. J Cardiovasc Magn
Reson 2006;8:361–6.
15. James CA, Bhonsale A, Tichnell C, et al. Exercise
increases age-related penetrance and arrhythmic
risk in arrhythmogenic right ventricular dysplasia/
cardiomyopathy-associated desmosomal mutation
carriers. J Am Coll Cardiol 2013;62:1290–7.
16. te Riele AS, Bhonsale A, James CA, et al.
Incremental value of cardiac magnetic resonanceimaging in arrhythmic risk stratiﬁcation of
arrhythmogenic right ventricular dysplasia/
cardiomyopathy-associated desmosomal muta-
tion carriers. J Am Coll Cardiol 2013;62:1761–9.
17. Protonotarios N, Anastasakis A, Antoniades L,
et al. Arrhythmogenic right ventricular cardio-
myopathy/dysplasia on the basis of the revised
diagnostic criteria in affected families with
desmosomal mutations. Eur Heart J 2011;32:
1097–104.
18. te Riele AS, James CA, Bhonsale A, et al.
Malignant arrhythmogenic right ventricular
dysplasia/cardiomyopathy with a normal 12-lead
electrocardiogram: a rare but underrecognized
clinical entity. Heart Rhythm 2013;10:1484–91.
19. Marcus FI, Zareba W, Calkins H, et al.
Arrhythmogenic right ventricular cardiomyopathy/
dysplasia clinical presentation and diagnostic
evaluation: results from the North American
Multidisciplinary Study. Heart Rhythm 2009;6:
984–92.
20. Pilmer CM, Kirsh JA, Hildebrandt D, Krahn AD,
Gow RM. Sudden cardiac death in children and
adolescents between 1 and 19 years of age. Heart
Rhythm 2014;11:239–45.
21. Quarta G, Muir A, Pantazis A, et al. Familial
evaluation in arrhythmogenic right ventricular
cardiomyopathy: impact of genetics and revised
task force criteria. Circulation 2011;123:2701–9.
KEY WORDS cardiomyopathy,
electrocardiography, magnetic resonance
imaging, progression, screening
APPENDIX For supplemental ﬁgures and
tables, please see the online version of this
article.
